| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 10968471 | Vaccine | 2011 | 7 Pages |
Abstract
⺠The CYD tetravalent dengue vaccine candidate is in clinical phase III. ⺠The 4 chimeric CYD vaccine viruses were fully sequenced throughout manufacturing. ⺠Complete genetic stability (no mutations) was seen from seed to bulk lots. ⺠At late amplification passages, rare incomplete nucleotide variations were detected. ⺠The in vivo emergence of mutant viruses after vaccination is highly unlikely.
Keywords
Related Topics
Life Sciences
Immunology and Microbiology
Immunology
Authors
N. Mantel, Y. Girerd, C. Geny, I. Bernard, J. Pontvianne, J. Lang, V. Barban,